Huiqing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huiqing Li has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Zhenhai Cui
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 shared publicationsYang Chen
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 shared publicationsKangli Xiao
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 shared publicationsJuan Zheng
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
4 shared publicationsNingjie Shi
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 shared publicationsSiqi Wang
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 shared publications
Latest Publications
- Open Access
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1691509
Metabolic factors influencing the efficacy of recombinant human growth hormone therapy in children with short stature
Objective: This study analyzed metabolic indicators and height gain in short-statured children within the first year of recombinant human growth hormone (rhGH) therapy, identifying predictive factors for treatment efficacy. Methods: A retrospective analysis of 72 children with short stature (growth hormone deficiency or idiopathic short stature) receiving rhGH therapy (January 2022 to January 2024) was performed. Data included height, weight, age, skeletal age (SA), and laboratory results (IGF1, fasting glucose, insulin, C-peptide, thyroid function, lipids). Analyses focused on height standard deviation score (HSDS), HSDS for SA, and factors associated with 12-month changes in HSDS for SA (△HSDS for SA). Results: The mean initial rhGH dose was 0.053 ± 0.010mg/kg/day, with a mean starting age of 8.36 ± 2.24 years. Significant increases in HSDS and HSDS for SA were observed after 12 months. △HSDS for SA negatively correlated with baseline homeostasis model assessment of insulin resistance (HOMA-IR) and fasting insulin, and positively correlated with baseline free triiodothyronine (FT3). Children with △HSDS for SA>0.5 had lower baseline insulin and HOMA-IR, and higher FT3, high-density lipoprotein cholesterol (HDL), and hemoglobin. Conclusions: Insulin resistance, hyperinsulinemia, FT3, and HDL determine rhGH efficacy in short-statured children. Metabolic profiling optimizes rhGH therapy, and targeting insulin resistance may improve growth outcomes.
- 6 November 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1691509
Open AccessMetabolic factors influencing the efficacy of recombinant human growth hormone therapy in children with short stature
Objective: This study analyzed metabolic indicators and height gain in short-statured children within the first year of recombinant human growth hormone (rhGH) therapy, identifying predictive factors for treatment efficacy. Methods: A retrospective analysis of 72 children with short stature (growth hormone deficiency or idiopathic short stature) receiving rhGH therapy (January 2022 to January 2024) was performed. Data included height, weight, age, skeletal age (SA), and laboratory results (IGF1, fasting glucose, insulin, C-peptide, thyroid function, lipids). Analyses focused on height standard deviation score (HSDS), HSDS for SA, and factors associated with 12-month changes in HSDS for SA (△HSDS for SA). Results: The mean initial rhGH dose was 0.053 ± 0.010mg/kg/day, with a mean starting age of 8.36 ± 2.24 years. Significant increases in HSDS and HSDS for SA were observed after 12 months. △HSDS for SA negatively correlated with baseline homeostasis model assessment of insulin resistance (HOMA-IR) and fasting insulin, and positively correlated with baseline free triiodothyronine (FT3). Children with △HSDS for SA>0.5 had lower baseline insulin and HOMA-IR, and higher FT3, high-density lipoprotein cholesterol (HDL), and hemoglobin. Conclusions: Insulin resistance, hyperinsulinemia, FT3, and HDL determine rhGH efficacy in short-statured children. Metabolic profiling optimizes rhGH therapy, and targeting insulin resistance may improve growth outcomes.
- Open Access
- 31 August 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1231520
Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis
Chronic inflammation and fibrosis are significant factors in the pathogenesis of metabolic-associated fatty liver disease (MAFLD). In this study, we conducted a bibliometric analysis of publications on inflammation and fibrogenesis in MAFLD, with a focus on reporting publication trends. Our findings indicate that the USA and China are the most productive countries in the field, with the University of California San Diego being the most productive institution. Over the past 23 years, Prof. Diehl AM has published 25 articles that significantly contributed to the research community. Notably, the research focus of the field has shifted from morbid obesity and adiponectin to metabolic syndrome, genetics, and microbiome. Our study provides a comprehensive and objective summary of the historical characteristics of research on inflammation and fibrogenesis in MAFLD, which will be of interest to scientific researchers in this field.
- 31 August 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1231520
Open AccessStudy on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis
Chronic inflammation and fibrosis are significant factors in the pathogenesis of metabolic-associated fatty liver disease (MAFLD). In this study, we conducted a bibliometric analysis of publications on inflammation and fibrogenesis in MAFLD, with a focus on reporting publication trends. Our findings indicate that the USA and China are the most productive countries in the field, with the University of California San Diego being the most productive institution. Over the past 23 years, Prof. Diehl AM has published 25 articles that significantly contributed to the research community. Notably, the research focus of the field has shifted from morbid obesity and adiponectin to metabolic syndrome, genetics, and microbiome. Our study provides a comprehensive and objective summary of the historical characteristics of research on inflammation and fibrogenesis in MAFLD, which will be of interest to scientific researchers in this field.
- Open Access
- 14 April 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14
Comparative efficacy of aromatase inhibitors and gonadotropin-releasing hormone analogue in increasing final height of idiopathic short stature boys: a network meta-analysis
Objective: To investigate the efficacy of monotherapy with AIs or GnRHa in improving the height of boys with idiopathic short stature (ISS).Method: We performed a systematic search in Pubmed, The Cochrane Library, Chinese National Knowledge Infrastructure databases, and Wanfang Database for eligible studies. The network meta-analysis was conducted using STATA software.Results: We identified a total of four studies that included 136 individuals. We used FAH/PAH as the main outcome of final height. The results revealed a statistically higher final height after treatment with AI or GnRHa in idiopathic short stature children(MD= 4.63, 95% CI[3.29,5.96]). In network meta-analysis, the direct and indirect comparison between AI and GnRHa was presented in the forest plot. Compared with control group, both AI and GnRHa were effective in increasing the final height, with the mean effect of 4.91(95%CI:1.10,8.17) and 5.55(95%CI:1.12,9.98) respectively. However, there was no statistical difference between the GnRHa and AI treatment, of which the mean effect was 0.65(95%CI: -4.30,5.60).Conclusion: Both AIs and GnRHa monotherapy were effective in augmenting the final height of boys with idiopathic short stature when compared to placebo groups. However, there was no statistical difference between the GnRHa and AI treatments.
- 14 April 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14
Open AccessComparative efficacy of aromatase inhibitors and gonadotropin-releasing hormone analogue in increasing final height of idiopathic short stature boys: a network meta-analysis
Objective: To investigate the efficacy of monotherapy with AIs or GnRHa in improving the height of boys with idiopathic short stature (ISS).Method: We performed a systematic search in Pubmed, The Cochrane Library, Chinese National Knowledge Infrastructure databases, and Wanfang Database for eligible studies. The network meta-analysis was conducted using STATA software.Results: We identified a total of four studies that included 136 individuals. We used FAH/PAH as the main outcome of final height. The results revealed a statistically higher final height after treatment with AI or GnRHa in idiopathic short stature children(MD= 4.63, 95% CI[3.29,5.96]). In network meta-analysis, the direct and indirect comparison between AI and GnRHa was presented in the forest plot. Compared with control group, both AI and GnRHa were effective in increasing the final height, with the mean effect of 4.91(95%CI:1.10,8.17) and 5.55(95%CI:1.12,9.98) respectively. However, there was no statistical difference between the GnRHa and AI treatment, of which the mean effect was 0.65(95%CI: -4.30,5.60).Conclusion: Both AIs and GnRHa monotherapy were effective in augmenting the final height of boys with idiopathic short stature when compared to placebo groups. However, there was no statistical difference between the GnRHa and AI treatments.
- Open Access
- 21 February 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 856002
Corrigendum: Case Report: A Chinese Family of Woodhouse-Sakati Syndrome With Diabetes Mellitus, With a Novel Biallelic Deletion Mutation of the DCAF17 Gene
Corrigendum: Case Report: A Chinese Family of Woodhouse-Sakati Syndrome With Diabetes Mellitus, With a Novel Biallelic Deletion Mutation of the DCAF17 Gene
- 21 February 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 856002
Open AccessCorrigendum: Case Report: A Chinese Family of Woodhouse-Sakati Syndrome With Diabetes Mellitus, With a Novel Biallelic Deletion Mutation of the DCAF17 Gene
Corrigendum: Case Report: A Chinese Family of Woodhouse-Sakati Syndrome With Diabetes Mellitus, With a Novel Biallelic Deletion Mutation of the DCAF17 Gene
- 1 February 2022
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 38 (4) , e3519
The association of obesity with the progression and outcome of COVID‐19: The insight from an artificial‐intelligence‐based imaging quantitative analysis on computed tomography
Aims: To explore the association of obesity with the progression and outcome of coronavirus disease 2019 (COVID‐19) at the acute period and 5‐month follow‐up from the perspectives of computed tomography (CT) imaging with artificial intelligence (AI)‐based quantitative evaluation, which may help to predict the risk of obese COVID‐19 patients progressing to severe and critical disease.Materials and Methods: This retrospective cohort enrolled 213 hospitalized COVID‐19 patients. Patients were classified into three groups according to their body mass index (BMI): normal weight (from 18.5 to 2), overweight (from 24 to 2) and obesity (≥28 kg/m2).Results: Compared with normal‐weight patients, patients with higher BMI were associated with more lung involvements in lung CT examination (lung lesions volume [cm3], normal weight vs. overweight vs. obesity; 175.5[34.0–414.9] vs. 261.7[73.3–576.2] vs. 395.8[101.6–1135.6]; p = 0.002), and were more inclined to deterioration at the acute period. At the 5‐month follow‐up, the lung residual lesion was more serious (residual total lung lesions volume [cm3], normal weight vs. overweight vs. obesity; 4.8[0.0–27.4] vs. 10.7[0.0–55.5] vs. 30.1[9.5–91.1]; p = 0.015), and the absorption rates were lower for higher BMI patients (absorption rates of total lung lesions volume [%], normal weight vs. overweight vs. obesity; 99.6[94.0–100.0] vs. 98.9[85.2–100.0] vs. 88.5[66.5–95.2]; p = 0.013). The clinical‐plus‐AI parameter model was superior to the clinical‐only parameter model in the prediction of disease deterioration (areas under the ROC curve, 0.884 vs. 0.794, p < 0.05).Conclusions: Obesity was associated with severe pneumonia lesions on CT and adverse clinical outcomes. The AI‐based model with combinational use of clinical and CT parameters had incremental prognostic value over the clinical parameters alone.
- 1 February 2022
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 38 (4) , e3519
The association of obesity with the progression and outcome of COVID‐19: The insight from an artificial‐intelligence‐based imaging quantitative analysis on computed tomography
Aims: To explore the association of obesity with the progression and outcome of coronavirus disease 2019 (COVID‐19) at the acute period and 5‐month follow‐up from the perspectives of computed tomography (CT) imaging with artificial intelligence (AI)‐based quantitative evaluation, which may help to predict the risk of obese COVID‐19 patients progressing to severe and critical disease.Materials and Methods: This retrospective cohort enrolled 213 hospitalized COVID‐19 patients. Patients were classified into three groups according to their body mass index (BMI): normal weight (from 18.5 to 2), overweight (from 24 to 2) and obesity (≥28 kg/m2).Results: Compared with normal‐weight patients, patients with higher BMI were associated with more lung involvements in lung CT examination (lung lesions volume [cm3], normal weight vs. overweight vs. obesity; 175.5[34.0–414.9] vs. 261.7[73.3–576.2] vs. 395.8[101.6–1135.6]; p = 0.002), and were more inclined to deterioration at the acute period. At the 5‐month follow‐up, the lung residual lesion was more serious (residual total lung lesions volume [cm3], normal weight vs. overweight vs. obesity; 4.8[0.0–27.4] vs. 10.7[0.0–55.5] vs. 30.1[9.5–91.1]; p = 0.015), and the absorption rates were lower for higher BMI patients (absorption rates of total lung lesions volume [%], normal weight vs. overweight vs. obesity; 99.6[94.0–100.0] vs. 98.9[85.2–100.0] vs. 88.5[66.5–95.2]; p = 0.013). The clinical‐plus‐AI parameter model was superior to the clinical‐only parameter model in the prediction of disease deterioration (areas under the ROC curve, 0.884 vs. 0.794, p < 0.05).Conclusions: Obesity was associated with severe pneumonia lesions on CT and adverse clinical outcomes. The AI‐based model with combinational use of clinical and CT parameters had incremental prognostic value over the clinical parameters alone.
- Open Access
- 23 December 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12, 770871
Case Report: A Chinese Family of Woodhouse-Sakati Syndrome With Diabetes Mellitus, With a Novel Biallelic Deletion Mutation of the DCAF17 Gene
Woodhouse–Sakati syndrome (WSS) (OMIM#241080) is a rare multi-system autosomal recessive disease with homozygous mutation of the DCAF17 gene. The main features of WSS include diabetes, hypogonadism, alopecia, deafness, intellectual disability and progressive extrapyramidal syndrome. We identified a WSS family with a novel DCAF17 gene mutation type in China. Two unconsanguineous siblings from the Chinese Han family exhibiting signs and symptoms of Woodhouse-Sakati syndrome were presented for evaluation. Whole-exome sequencing revealed a homozygous deletion NM_025000.4:c.1488_1489delAG in the DCAF17 gene, which resulted in a frameshift mutation that led to stop codon formation. We found that the two patients exhibited low insulin and C-peptide release after glucose stimulation by insulin and C-peptide release tests. These findings indicate that the DCAF17 gene mutation may cause pancreatic β cell functional impairment and contribute to the development of diabetes.
- 23 December 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12, 770871
Open AccessCase Report: A Chinese Family of Woodhouse-Sakati Syndrome With Diabetes Mellitus, With a Novel Biallelic Deletion Mutation of the DCAF17 Gene
Woodhouse–Sakati syndrome (WSS) (OMIM#241080) is a rare multi-system autosomal recessive disease with homozygous mutation of the DCAF17 gene. The main features of WSS include diabetes, hypogonadism, alopecia, deafness, intellectual disability and progressive extrapyramidal syndrome. We identified a WSS family with a novel DCAF17 gene mutation type in China. Two unconsanguineous siblings from the Chinese Han family exhibiting signs and symptoms of Woodhouse-Sakati syndrome were presented for evaluation. Whole-exome sequencing revealed a homozygous deletion NM_025000.4:c.1488_1489delAG in the DCAF17 gene, which resulted in a frameshift mutation that led to stop codon formation. We found that the two patients exhibited low insulin and C-peptide release after glucose stimulation by insulin and C-peptide release tests. These findings indicate that the DCAF17 gene mutation may cause pancreatic β cell functional impairment and contribute to the development of diabetes.
- Open Access
- 15 November 2021
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 21 (1) , 1-9
Suppression of the hypothalamic-pituitary-thyroid axis is associated with the severity of prognosis in hospitalized patients with COVID-19
Background: The outbreak of severe acute respiratory syndrome novel coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide. SARS-CoV-2 has been found to cause multiple organ damage; however, little attention has been paid to the damage to the endocrine system caused by this virus, and the subsequent impact on prognosis. This may be the first research on the hypothalamic-pituitary-thyroid (HPT) axis and prognosis in coronavirus disease 2019 (COVID-19). Methods: In this retrospective observational study, 235 patients were admitted to the hospital with laboratory-confirmed SARS-CoV-2 infection from 22 January to 17 March 2020. Clinical characteristics, laboratory findings, and treatments were obtained from electronic medical records with standard data collection forms and compared among patients with different thyroid function status. Results: Among 235 patients, 17 (7.23%) had subclinical hypothyroidism, 11 (4.68%) severe non-thyroidal illness syndrome (NTIS), and 23 (9.79%) mild to moderate NTIS. Composite endpoint events of each group, including mortality, admission to the ICU, and using IMV were observed. Compared with normal thyroid function, the hazard ratios (HRs) of composite endpoint events for mild to moderate NTIS, severe NTIS, subclinical hypothyroidism were 27.3 (95% confidence interval [CI] 7.07–105.7), 23.1 (95% CI 5.75–92.8), and 4.04 (95% CI 0.69–23.8) respectively. The multivariate-adjusted HRs for acute cardiac injury among patients with NTF, subclinical hypothyroidism, severe NTIS, and mild to moderate NTIS were 1.00, 1.68 (95% CI 0.56–5.05), 4.68 (95% CI 1.76–12.4), and 2.63 (95% CI 1.09–6.36) respectively. Conclusions: Our study shows that the suppression of the HPT axis could be a common complication in COVID-19 patients and an indicator of the severity of prognosis. Among the three different types of thyroid dysfunction with COVID-19, mild to moderate NTIS and severe NTIS have a higher risk of severe outcomes compared with subclinical hypothyroidism.
- 15 November 2021
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 21 (1) , 1-9
Open AccessSuppression of the hypothalamic-pituitary-thyroid axis is associated with the severity of prognosis in hospitalized patients with COVID-19
Background: The outbreak of severe acute respiratory syndrome novel coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide. SARS-CoV-2 has been found to cause multiple organ damage; however, little attention has been paid to the damage to the endocrine system caused by this virus, and the subsequent impact on prognosis. This may be the first research on the hypothalamic-pituitary-thyroid (HPT) axis and prognosis in coronavirus disease 2019 (COVID-19). Methods: In this retrospective observational study, 235 patients were admitted to the hospital with laboratory-confirmed SARS-CoV-2 infection from 22 January to 17 March 2020. Clinical characteristics, laboratory findings, and treatments were obtained from electronic medical records with standard data collection forms and compared among patients with different thyroid function status. Results: Among 235 patients, 17 (7.23%) had subclinical hypothyroidism, 11 (4.68%) severe non-thyroidal illness syndrome (NTIS), and 23 (9.79%) mild to moderate NTIS. Composite endpoint events of each group, including mortality, admission to the ICU, and using IMV were observed. Compared with normal thyroid function, the hazard ratios (HRs) of composite endpoint events for mild to moderate NTIS, severe NTIS, subclinical hypothyroidism were 27.3 (95% confidence interval [CI] 7.07–105.7), 23.1 (95% CI 5.75–92.8), and 4.04 (95% CI 0.69–23.8) respectively. The multivariate-adjusted HRs for acute cardiac injury among patients with NTF, subclinical hypothyroidism, severe NTIS, and mild to moderate NTIS were 1.00, 1.68 (95% CI 0.56–5.05), 4.68 (95% CI 1.76–12.4), and 2.63 (95% CI 1.09–6.36) respectively. Conclusions: Our study shows that the suppression of the HPT axis could be a common complication in COVID-19 patients and an indicator of the severity of prognosis. Among the three different types of thyroid dysfunction with COVID-19, mild to moderate NTIS and severe NTIS have a higher risk of severe outcomes compared with subclinical hypothyroidism.
- Open Access
- 22 October 2020
- Published by Springer Nature in Research Square
Potential Biomarkers of Diabetic Kidney Disease Based on Weighted Gene Co-expression Network Analysis
Background: Diabetic kidney disease (DKD) is one of the serious complications of diabetes. However, there is no unified and clear understanding of the pathogenesis of DKD at present. The evidence suggests that genetic predispositions play a significant role in an individual’s susceptibility to DKD. WGCNA analysis may provide a new way to search for genes closely related to DKD. Methods: In this study we analysed key genes and pathways involved in DKD from RNA-seq count results using 23 peripheral blood samples from patients with DKD. Weighted gene co-expression network analysis (WGCNA) was performed with the WGCNA package.Results: We found turquoise and purple module were characterized as having the highest correlation with large proteinuria stage in DKD. Furthermore, the key genes, including DCN, F2R, LTBP2, B2M, PSMB8, and NLRC5, were evaluated through a protein-protein interaction (PPI) network combined with a co-expression network, which were expected to be potential diagnostic and therapeutic targets of DKD. Conclusions: These signalling pathways and hub genes will provide effective targets and ideas for further study of the pathogenesis of DKD and are expected to have roles in the prevention of, early screening for, and the treatment of DKD.
- 22 October 2020
- Published by Springer Nature in Research Square
Open AccessPotential Biomarkers of Diabetic Kidney Disease Based on Weighted Gene Co-expression Network Analysis
Background: Diabetic kidney disease (DKD) is one of the serious complications of diabetes. However, there is no unified and clear understanding of the pathogenesis of DKD at present. The evidence suggests that genetic predispositions play a significant role in an individual’s susceptibility to DKD. WGCNA analysis may provide a new way to search for genes closely related to DKD. Methods: In this study we analysed key genes and pathways involved in DKD from RNA-seq count results using 23 peripheral blood samples from patients with DKD. Weighted gene co-expression network analysis (WGCNA) was performed with the WGCNA package.Results: We found turquoise and purple module were characterized as having the highest correlation with large proteinuria stage in DKD. Furthermore, the key genes, including DCN, F2R, LTBP2, B2M, PSMB8, and NLRC5, were evaluated through a protein-protein interaction (PPI) network combined with a co-expression network, which were expected to be potential diagnostic and therapeutic targets of DKD. Conclusions: These signalling pathways and hub genes will provide effective targets and ideas for further study of the pathogenesis of DKD and are expected to have roles in the prevention of, early screening for, and the treatment of DKD.
- Open Access
- 1 July 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (27) , e16225
Identification of miRNAs-genes regulatory network in diabetic nephropathy based on bioinformatics analysis
MicroRNAs (miRNAs) play a great contribution to the development of diabetic nephropathy (DN). The aim of this study was to explore potential miRNAs-genes regulatory network and biomarkers for the pathogenesis of DN using bioinformatics methods. Gene expression profiling data related to DN (GSE1009) was obtained from the Gene Expression Omnibus (GEO) database, and then differentially expressed genes (DEGs) between DN patients and normal individuals were screened using GEO2R, followed by a series of bioinformatics analyses, including identifying key genes, conducting pathway enrichment analysis, predicting and identifying key miRNAs, and establishing regulatory relationships between key miRNAs and their target genes. A total of 600 DEGs associated with DN were identified. An additional 7 key DEGs, including 6 downregulated genes, such as vascular endothelial growth factor α (VEGFA) and COL4A5, and 1 upregulated gene (CCL19), were identified in another dataset (GSE30528) from glomeruli samples. Pathway analysis showed that the down- and upregulated DEGs were enriched in 14 and 6 pathways, respectively, with 7 key genes mainly involved in extracellular matrix–receptor interaction, PI3K/Akt signaling, focal adhesion, and Rap1 signaling. The relationships between miRNAs and target genes were constructed, showing that miR-29 targeted COL4A and VEGFA, miR-200 targeted VEGFA, miR-25 targeted ITGAV, and miR-27 targeted EGFR. MiR-29 and miR-200 may play important roles in DN. VEGFA and COL4A5 were targeted by miR-29 and VEGFA by miR-200, which may mediate multiple signaling pathways leading to the pathogenesis and development of DN.
- 1 July 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (27) , e16225
Open AccessIdentification of miRNAs-genes regulatory network in diabetic nephropathy based on bioinformatics analysis
MicroRNAs (miRNAs) play a great contribution to the development of diabetic nephropathy (DN). The aim of this study was to explore potential miRNAs-genes regulatory network and biomarkers for the pathogenesis of DN using bioinformatics methods. Gene expression profiling data related to DN (GSE1009) was obtained from the Gene Expression Omnibus (GEO) database, and then differentially expressed genes (DEGs) between DN patients and normal individuals were screened using GEO2R, followed by a series of bioinformatics analyses, including identifying key genes, conducting pathway enrichment analysis, predicting and identifying key miRNAs, and establishing regulatory relationships between key miRNAs and their target genes. A total of 600 DEGs associated with DN were identified. An additional 7 key DEGs, including 6 downregulated genes, such as vascular endothelial growth factor α (VEGFA) and COL4A5, and 1 upregulated gene (CCL19), were identified in another dataset (GSE30528) from glomeruli samples. Pathway analysis showed that the down- and upregulated DEGs were enriched in 14 and 6 pathways, respectively, with 7 key genes mainly involved in extracellular matrix–receptor interaction, PI3K/Akt signaling, focal adhesion, and Rap1 signaling. The relationships between miRNAs and target genes were constructed, showing that miR-29 targeted COL4A and VEGFA, miR-200 targeted VEGFA, miR-25 targeted ITGAV, and miR-27 targeted EGFR. MiR-29 and miR-200 may play important roles in DN. VEGFA and COL4A5 were targeted by miR-29 and VEGFA by miR-200, which may mediate multiple signaling pathways leading to the pathogenesis and development of DN.
- 1 November 2018
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 32 (11) , 985-994
Liraglutide protects β-cell function by reversing histone modification of Pdx-1 proximal promoter in catch-up growth male rats
- 1 November 2018
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 32 (11) , 985-994
Liraglutide protects β-cell function by reversing histone modification of Pdx-1 proximal promoter in catch-up growth male rats